Nieuws

Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...
Ozempic maker Novo replaces CEO after share price fall
Jorgensen became CEO in January 2017 and the company’s market capitalization has more than tripled during his tenure. Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, but ...
Novo Nordisk Boots CEO After Stock Falls 50%. It’s an Unusual Move for the Wegovy Drugmaker.
It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.
Instant View: Novo Nordisk CEO's surprise exit after setbacks in weight-loss market
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...
Novo Nordisk CEO to Step Down as Market Challenges Mount — Update
"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk board and Lars Fruergaard Jorgensen have jointly concluded that ...